Should You Buy Collegium Pharmaceutical, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Collegium Pharmaceutical, Inc. (COLL) scores a robust 8.8/10 on our 32-signal Quality of Company framework. At the current market price of $21.84 and a $677M market cap, our analysis maps this fundamental strength against 13 institutional-grade models to determine if a sufficient margin of safety exists.
The short answer: 7 of 8 CirclFi valuation models project upside for Collegium Pharmaceutical, Inc. (COLL) at $21.84 — the model consensus leans bullish, with a Quality Score of 8.8/10 and Value-Trap risk of 45/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Collegium Pharmaceutical, Inc. (COLL) in 2026?
What Is the Bull Case vs the Bear Case for Collegium Pharmaceutical, Inc. (COLL)?
| Bull case — $88.06 target (+303.2%) | Bear case — $9.61 target (-56.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Collegium Pharmaceutical, Inc.'s score of 8.8/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Value Trap algorithm, the stock shows moderate caution signals, meaning investors should verify that apparent undervaluation isn't masking declining business quality. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +189.5% across 7 bullish models from the current price of $21.84. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $9.61 (-56.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the CUCE model targets a fair value of $88.06 (+303.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +359.2% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Collegium Pharmaceutical, Inc.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: clinical trial failure represents a meaningful risk for Collegium Pharmaceutical, Inc. and its Drug Manufacturers - Specialty & Generic peers. |
How Does COLL Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: RDY · PAHC · ELTP · ALKS · ANIP · HLN · ANIK · TKNO · CTOR · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like COLL on Quality?
Closest companies to COLL’s Quality of Company score of 8.8/10, across all industries.
- INGR — Ingredion Incorporated (QOC 8.8) · analysis
- TTD — The Trade Desk, Inc. (QOC 8.8) · analysis
- ABT — Abbott Laboratories (QOC 8.8) · analysis
- EACO — EACO Corporation (QOC 8.8) · analysis
- HWKN — Hawkins, Inc. (QOC 8.8) · analysis
- EOG — EOG Resources, Inc. (QOC 8.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does COLL Appear In?
So Is Collegium Pharmaceutical, Inc. (COLL) Worth Buying in 2026?
The convergence of 8.8/10 quality, multi-model undervaluation (7/8 bullish, +189.5% median upside), and a median fair value of $63.22 vs. $21.84 current price makes Collegium Pharmaceutical, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Collegium Pharmaceutical, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About COLL Stock?
Should I buy COLL stock right now?
Based on CirclFi's multi-model analysis, 7 of 8 models see upside for COLL at $21.84. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.8/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Collegium Pharmaceutical, Inc.?
Key risks include: an elevated Value Trap score of 45/100, suggesting apparent undervaluation may mask deteriorating fundamentals; wide model disagreement (816% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does COLL compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, COLL holds a Quality Score of 8.8/10. Comparable companies include RDY (QOC 8.8), PAHC (QOC 8.7), ELTP (QOC 8.9). The relative ranking helps investors identify whether COLL offers better fundamental quality than alternatives in the same sector.
Is COLL a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. COLL's Quality Score of 8.8/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy COLL at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $9.61 to $88.06. At $21.84, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for COLL.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad